


U.S. Serial No. 09/284,424
Group Art Unit No. 1623






IN THE CLAIMS:

Please amend claims 1, 17, 18, 20 and 34 as follows:

(Thrice Amended) A compound of the Formula I




wherein R^1 is R^3OC- ,
 R^3CO- ,
 R^3SO_2- ,
 R^a
 $R^5NCH(R^6)CO-$,




each R^a is independently hydrogen, C_1 - C_6 alkyl, or $-(CH_2)_n$ aryl;

R^2 is $-(CRR)_n$ -aryl,
 $-(CRR)_n$ -X-aryl,
 $-(CRR)_n$ -(substituted-aryl),

U.S. Serial No. 09/284,424
Group Art Unit No. 1623



U.S. Serial No. 09/284,424
Group Art Unit No. 1623



each R is independently hydrogen, C_1 - C_6 alkyl, halogen or hydroxy;

X is O or S;

R^3 is C_1 - C_6 alkyl,

aryl,

$-(CHR)_n$ -aryl,

$-(CHR)_n$ -substituted aryl,

O

||

$-(CRR)_n$ COR^a,

$-(CRR)_n$ O(CH₂)_n-aryl,

cycloalkyl,


substituted cycloalkyl,

O

||


$-(CRR)_n$ CNR^aR^a,

U.S. Serial No. 09/284,424
Group Art Unit No. 1623



C1
cont'd

U.S. Serial No. 09/284,424
Group Art Unit No. 1623



each R' is independently C_1 - C_6 alkyl,
 C_1 - C_6 alkylaryl,
aryl, or
hydrogen;

each J is independently
- $NH-SO_2-(C_1-C_6\text{-alkyl})$,
- CO_2R^b ,
- $CONR^b R^b$,
- $SO_2NR^b R^b$, or
- SO_2R^b ;

each R^b is independently hydrogen, C_1 - C_6 alkyl, aryl, substituted aryl, arylalkyl, or
substituted arylalkyl;

R^4 is hydrogen,
 C_1 - C_6 alkyl,

$CH_3OC(=O)-$,
-phenyl, or


C_1 - C_6 alkyl $C(=O)-$;

R^5 is C_1 - C_6 alkyl- $CO-$,
- $(CH_2)_n$ aryl,


C_1 - C_6 -alkyl $C(=O)-$,
 C_1 - C_6 -alkyl- $X-(CH_2)_n CO-$,

C_1 - C_6 -alkyl- $X-(CH_2)_n OC(=O)-$,

U.S. Serial No. 09/284,424
Group Art Unit No. 1623



U.S. Serial No. 09/284,424
Group Art Unit No. 1623



R⁶ is hydrogen,

C₁-C₆ alkyl, -(CH₂)_n aryl, -(CH₂)_nCO₂R^a, or hydroxyl substituted C₁-C₆ alkyl;

R⁷ is hydrogen, -S-(C₁-C₆-alkyl), or -SO₂-(C₁-C₆-alkyl);

each n is independently 0 to 3, and the pharmaceutically acceptable, salts, esters, amides, and prodrugs thereof;

excluding the following compounds:

N-Benzyloxycarbonyl-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
 N-Benzyloxycarbonyl-L-aspartic acid 2,6-ditrifluoromethyl benzoyloxymethyl ketone;
 N-Benzyloxycarbonyl-L-aspartic acid 2,6-dichloro-3-(2-N-morpholinylethoxy)benzoyloxymethyl ketone;
 N-Benzyloxycarbonyl-L-aspartic acid 2,6-dimethoxybenzoyloxy methyl ketone;
 N-Benzyloxycarbonyl-L-aspartic acid 2,6-dichloro-3-(benzyloxy)benzoyloxymethyl ketone;
 N-Benzyloxycarbonyl-L-aspartic acid 2-acetamido-6-chlorobenzoyloxymethyl ketone;
 N-Benzyloxycarbonyl-L-aspartic acid 2,6-difluorobenzoyloxymethyl ketone;
 N-Benzyloxycarbonyl-L-aspartic acid 3-(N-butylsulfonamido)-2,6-dichlorobenzoyloxymethyl ketone;
 N-Benzyloxycarbonyl-L-aspartic acid 2,6-dichloro-3-sulfonamido benzoyloxymethyl ketone;
 N-Benzyloxycarbonyl-L-aspartic acid 3-(N-benzylsulfonamido)-2,6-dichlorobenzoyloxymethyl ketone;
 N-Benzyloxycarbonyl-L-aspartic acid 3-(N-(2-aminoacetamidoyl)-sulfonamido)-2,6-dichlorobenzoyloxymethyl ketone;
 N-Benzyloxycarbonyl-L-aspartic acid 2,6-dichloro-3-(N-morpholinylsulfonamido)benzoyloxymethyl ketone;
 N-Methoxycarbonyl-L-alanine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
 N-(2-thienyl)carbonyl-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;

U.S. Serial No. 09/284,424
Group Art Unit No. 1623

N-Methoxycarbonyl glycine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Methoxycarbonyl-L-phenylalanine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Methoxycarbonyl-L-valine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Methoxycarbonyl-L-histidine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Benzoyloxycarbonyl-L-valine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Benzoyloxycarbonyl-L-alanine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Benzoyloxycarbonyl-L-valine-L-alanine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-(2-Furonyl)carbonyl-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-(2-Furonyl)carbonyl-L-aspartic acid 2,6-dichloro-3-(N-morpholinylsulfonamido)benzoyloxymethyl ketone;
N-(3-Phenylpropionyl)-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Methoxycarbonyl-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-(4-N,N-dimethylaminomethyl)benzoyl-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Benzoyloxycarbonyl-D-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Methoxy-L-histidine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Methoxy-glycine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Methoxy-L-alanine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Methoxy-L-valine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Benzoyloxy-L-valine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Benzoyloxy-D-alanine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Benzoyloxy-L-alanine-L-alanine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Benzoyloxy-L-valine-L-alanine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-Benzoyloxy-D-alanine-L-alanine-L-aspartic acid 2,6-dichlorobenzoyloxymethyl ketone;
N-(N-phenylpropionyl-valinyl-alaninyl)-3-amino-4-oxo-5-(2,6-bis(trifluoromethyl)benzoyloxy) pentanoic acid;
N-(N-phenylpropionyl-valinyl-alaninyl)-3-amino-4-oxo-5-benzoyloxy pentanoic acid;
N-(N-Acetyl-tyrosinyl-valinyl-alaninyl)-3-amino-4-oxo-5-(pentafluorobenzoyloxy) pentanoic acid;
3-Phenylpropionyl-L-valine-L-alanine-aspartic acid 2-phenylethylcarbonyloxymethyl ketone;
Adamantane-1-carboxylic acid 3-[2-(2-benzoyloxycarbonylamino-3-methylbutyrylamino)-propionylamino]-4-carboxy-2-oxo-butyl ester;
Acridine-9-carboxylic acid 3-[2-(2-benzoyloxycarbonylamino-3-methylbutyrylamino)-propionylamino]-4-carboxy-2-oxo-butyl ester;
1H-Indole-3-carboxylic acid 3-[2-(2-benzoyloxycarbonylamino-3-methylbutyrylamino)-propionylamino]-4-carboxy-2-oxo-butyl ester;
2-Methyl-imidazo[1,2-a]pyridine-3-carboxylic acid 3-[2-(2-benzoyloxycarbonylamino-3-methylbutyrylamino)-propionylamino]-4-carboxy-2-oxo-butyl ester;
2-Methoxy-3-methyl-quinoline-4-carboxylic acid 3-[2-(2-benzoyloxycarbonylamino-3-methylbutyrylamino)-propionylamino]-4-carboxy-2-oxo-butyl ester;
1,3-Dimethyl-1H-indole-2-carboxylic acid 3-[2-(2-benzoyloxycarbonylamino-3-methylbutyrylamino)-propionylamino]-4-carboxy-2-oxo-butyl ester;

U.S. Serial No. 09/284,424
Group Art Unit No. 1623

C1
concl'd





~~9H-Xanthene-9-carboxylic acid 3-[2-(2-benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-4-carboxy-2-oxo-butyl ester;
3-[2-(2-Benzyloxycarbonylamino-3-methyl-butyrylamino)-propionylamino]-5-diphenylacetoxyl-4-oxo-pentanoic acid;
2,6-Dichloro-benzoic acid 3-(5-benzyloxycarbonylamino-naphthalene-1-sulfonylamino)-4-carboxy-2-oxo-butyl ester;
2,6-Dichloro-benzoic acid 3-[[2-(1-benzyloxycarbonylamino-2-methyl-propyl)-thiazole-4-carbonyl]-amino]-4-carboxy-2-oxo-butyl ester;
2,6-Dichloro-benzoic acid 3-[2-(3-benzyloxycarbonylamino-phenyl)-propionylamino]-4-carboxy-2-oxo-butyl ester;
2,6-Dichloro-benzoic acid 3-[(5-benzyloxycarbonylamino-1H-indole-3-carbonyl)-amino]-4-carboxy-2-oxo-butyl ester;
2,6-Dichloro-benzoic acid 3-[2-(6-benzyloxycarbonyloxy-naphthalen-2-yl)-propionylamino]-4-carboxy-2-oxo-butyl ester;
2,6-Dichloro-benzoic acid 3-(5-benzyloxycarbonylamino-naphthalene-1-sulfonylamino)-4-carboxy-2-oxo-butyl ester;
2,6-Dichloro-benzoic acid 3-[(5-benzyloxycarbonylamino-naphthalene-1-carbonyl)-amino]-4-carboxy-2-oxo-butyl ester;
2,6-Dichloro-benzoic acid 3-[(6-benzyloxycarbonylamino-5-oxo-octahydro-indolizine-3-carbonyl)-amino]-4-carboxy-2-oxo-butyl ester; and
2,6-Dichloro-benzoic acid 3-[(4-benzyloxycarbonylamino-cyclohexanecarbonyl)-amino]-4-carboxy-2-oxo-butyl ester.~~

17. (Amended) A compound according to Claim 1 wherein each R^a is hydrogen; R^1 is benzyloxycarbonyl; R^2 is aryl- $X(CRR)_n$, aryl- $(CRR)_n$, or cycloalkyl- $(CRR)_n$; n is 1, 2, or 3; X is O or S; and R is hydrogen, methyl, or benzyl.

- C2
18. (Amended) A compound according to Claim 1 wherein each R^a is hydrogen; R^1 is benzyloxycarbonyl; and R^3 is $-(CH_2)_n$ -naphthyl,
 $-(CH_2)_n$ -phenyl,
 $-(CH_2)_n$ -cycloalkyl,
 $-(CH_2)_nO(CH_2)_n$ -naphthyl,
 $-(CH_2)_nO(CH_2)_n$ -phenyl, or
 $-(CH_2)_nS(CH_2)_n$ -phenyl.

U.S. Serial No. 09/284,424
Group Art Unit No. 1623

20. (Twice Amended) A compound in accordance with Claim 1 wherein each R^a is hydrogen; and
R¹ is benzyloxycarbonyl,



34. (Amended) The compounds:

(S)-5-(Naphthalene-1-yl-acetoxy)-4-oxo-3-phenylacetyl-amino-pentanoic acid;
3-[(2-Carbamoyl-cyclopentanecarbonyl)-amino]-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid;
3-[(3-Carbamoyl-bicyclo[2.2.1]heptane-2-carbonyl)-amino]-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid;
3-(3-Methanesulfonyl-2-methyl-propionyl-amino)-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid;
3-(3-Benzenesulfonyl-2-methyl-propionyl-amino)-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid;
3-Butyrylamino-5-(naphthalen-2-yl-acetoxy)-4-oxo-pentanoic acid;
3-Acetyl-amino-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid;
3-(3-Methanesulfonyl-2-methyl-propionyl-amino)-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid;
3-(3-Methyl-butyrylamino)-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid;


U.S. Serial No. 09/284,424
Group Art Unit No. 1623

C4
cond

3-(3-Carbamoyl-propionylamino)-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid;
[S-(R*,R*)]-3-(3-Acetylsulfanyl-2-methyl-propionylamino)-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid; and
trans-3-[(3-Carbamoyl-cyclopentanecarbonyl)-amino]-5-(naphthalen-1-yl-acetoxy)-4-oxo-pentanoic acid.



Please add new claims 52 - 54 as follows:

52 (New) A compound of the Formula I



C5

wherein R¹ is R³OC-,
R³CO-,
R³SO₂-,
R^a
|
R⁵NCHR⁶CO-,









each R^a is independently hydrogen, C₁-C₆ alkyl, or -(CH₂)_n aryl;


R² is -(CRR)_n-aryl,

U.S. Serial No. 09/284,424
Group Art Unit No. 1623

$-(CRR)_n-X-aryl$,
 $-(CRR)_n-(substituted-aryl)$, provided that the aryl group is not substituted with
 alkoxy, halogen, or trifluoromethyl,
 $-(CRR)_n-X-(substituted-aryl)$,
 $-(CRR)_n-aryl-aryl$,
 $-(CRR)_n-aryl-(CH_2)_n-aryl$,
 $-(CRR)_n-CH(aryl)_2$,
 $-(CRR)_n-cycloalkyl$,
 $-(CRR)_n-X-cycloalkyl$,



U.S. Serial No. 09/284,424
Group Art Unit No. 1623



each R is independently hydrogen, C₁-C₆ alkyl, halogen or hydroxy;

X is O or S;

R³ is C₁-C₆ alkyl,

aryl,

-(CHR)_n-aryl,

-(CHR)_n-substituted aryl,

O

||

-(CRR)_nCOR^a,

-(CRR)_nO(CH₂)_n-aryl,

cycloalkyl,


substituted cycloalkyl,

O

||


-(CRR)_nCNR^aR^a,

U.S. Serial No. 09/284,424
Group Art Unit No. 1623



C5
contd

U.S. Serial N . 09/284,424
Group Art Unit No. 1623





each R' is independently C₁-C₆ alkyl,
C₁-C₆ alkylaryl,
aryl, or
hydrogen;



each J is independently
-NH-SO₂-(C₁-C₆-alkyl),
-CO₂R^b,
-CONR^bR^b,
-SO₂NR^bR^b, or
-SO₂R^b;

each R^b is independently hydrogen, C₁-C₆ alkyl, aryl, substituted aryl, arylalkyl, or
substituted arylalkyl;


R⁴ is hydrogen,
C₁-C₆ alkyl,




R⁵ is C₁-C₆ alkyl-CO-,
-(CH₂)_n aryl,



U.S. Serial No. 09/284,424
Group Art Unit No. 1623



U.S. Serial No. 09/284,424
Group Art Unit No. 1623





R⁶ is hydrogen,

C₁-C₆ alkyl, -(CH₂)_n aryl, -(CH₂)_nCO₂R^a, or hydroxyl substituted C₁-C₆ alkyl;

R⁷ is hydrogen, -S-(C₁-C₆-alkyl), or -SO₂-(C₁-C₆-alkyl);


each n is independently 0 to 3,

provided that when R^{5a} is



and the pharmaceutically acceptable, salts, esters, amides, and prodrugs thereof.


53. (New) A compound of the Formula I



I

wherein R¹ is R³OC-,

U.S. Serial No. 09/284,424
Group Art Unit No. 1623



each R^a is independently hydrogen, C_1-C_6 alkyl, or $-(CH_2)_n$ aryl;

R^2 is $-(CRR)_n$ -aryl,

$-(CRR)_n$ -X-aryl,

$-(CRR)_n$ -X-(substituted-aryl),

$-(CRR)_n$ -aryl-aryl,

$-(CRR)_n$ -aryl- $(CH_2)_n$ -aryl,

$-(CRR)_n$ -CH(aryl)₂,







$-(CRR)_n$ -cycloalkyl,

$-(CRR)_n$ -X-cycloalkyl,

$-(CRR)_n$ -CH
 $\begin{matrix} (CH_2)_n\text{-aryl} \\ (CH_2)_n\text{-aryl} \end{matrix}$


$-(CRR)_n$ -CH
 $\begin{matrix} (CH_2)_n\text{-substituted aryl} \\ (CH_2)_n\text{-aryl} \end{matrix}$

U.S. Serial No. 09/284,424
Group Art Unit No. 1623



C5
cont'd

U.S. Serial No. 09/284,424
Group Art Unit No. 1623



each R is independently hydrogen, C₁-C₆ alkyl, halogen or hydroxy;

X is O or S;

R³ is C₁-C₆ alkyl,

aryl,

-(CHR)_n-aryl,

-(CHR)_n-substituted aryl,

O

||

-(CRR)_nCOR^a,

-(CRR)_nO(CH₂)_n-aryl,

cycloalkyl,

substituted cycloalkyl,

O

||

-(CRR)_nCNR^aR^a,

O

||

-(CRR)_n-S-(CH₂)_n aryl,

O

O

||

-(CRR)_n-SC₁-C₆ alkyl,

O

||

R^a

|

I-CH₂CH-


O

||

-(CRR)_nS(CH₂)_nCOR^a,

C5
contd

U.S. Serial No. 09/284,424
Group Art Unit No. 1623



each R' is independently C₁-C₆ alkyl,
C₁-C₆ alkylaryl,
aryl, or
hydrogen;
each J is independently
-NH-SO₂-(C₁-C₆-alkyl),
-CO₂R^b,
-CONR^bR^b,
-SO₂NR^bR^b, or

U.S. Serial No. 09/284,424
Group Art Unit No. 1623

~~-SO₂R^b;~~

~~each R^b is independently hydrogen, C₁-C₆ alkyl, aryl, substituted aryl, arylalkyl, or substituted arylalkyl;~~

~~R⁴ is hydrogen,
C₁-C₆ alkyl,~~

~~$\begin{array}{c} \text{O} \\ \parallel \\ \text{CH}_3\text{OC}-, \\ \text{-phenyl, or} \end{array}$~~

~~$\begin{array}{c} \text{O} \\ \parallel \\ \text{C}_1\text{-C}_6 \text{ alkyl C}-; \end{array}$~~

~~R⁵ is C₁-C₆ alkyl-CO-,
-(CH₂)_n aryl,~~

~~$\begin{array}{c} \text{O} \\ \parallel \\ \text{C}_1\text{-C}_6\text{-alkyl OC}-, \\ \text{C}_1\text{-C}_6\text{-alkyl-X-(CH}_2\text{)}_n\text{CO}, \end{array}$~~

~~$\begin{array}{c} \text{O} \\ \parallel \\ \text{C}_1\text{-C}_6\text{-alkyl-X-(CH}_2\text{)}_n\text{OC}-, \end{array}$~~

~~$\begin{array}{c} \text{O} \\ \parallel \\ \text{-C(CRR)}_n\text{aryl}, \end{array}$~~

~~$\begin{array}{c} \text{O} \\ \parallel \\ \text{-CNR}^a\text{R}^a, \end{array}$~~


~~$\begin{array}{c} \text{O} \\ \parallel \\ \text{-SC}_1\text{-C}_6 \text{ alkyl}, \end{array}$~~

~~$\begin{array}{c} \text{O} \quad \text{O} \\ \parallel \quad \parallel \\ \text{-C(CH}_2\text{)}_n\text{CNR}^a\text{R}^a, \end{array}$~~


~~$\begin{array}{c} \text{O} \\ \parallel \\ \text{-CO(CH}_2\text{)}_n \text{ aryl}, \end{array}$~~

~~$\begin{array}{c} \text{O} \\ \parallel \\ \text{-CO(CH}_2\text{)}_n \text{ substituted aryl}, \end{array}$~~

U.S. Serial No. 09/284,424
Group Art Unit No. 1623



R^{5a} is




R⁶ is hydrogen,

C₁-C₆ alkyl, $-(\text{CH}_2)_n$ aryl, $-(\text{CH}_2)_n \text{CO}_2\text{R}^a$, or hydroxyl substituted C₁-C₆ alkyl;

R⁷ is hydrogen, $-\text{S}-(\text{C}_1\text{-C}_6\text{-alkyl})$, or $-\text{SO}_2-(\text{C}_1\text{-C}_6\text{-alkyl})$;

each n is independently 0 to 3,

provided that when R^{5a} is




then n is 0, 2, or 3, and

provided that when R^{5a} is

U.S. Serial No. 09/284,424
Group Art Unit No. 1623






$C(CH_2)_n$ aryl,
then n is 0, 1, or 3,
and the pharmaceutically acceptable, salts, esters, amides, and prodrugs thereof.

54. (New) A compound of the Formula I



1


wherein R^1 is $R^3OC(=O)-$,
 R^3CO- ,
 R^3SO_2- ,
 R^a
|
 $R^5NCH(R^6)CO-$,



each R^a is independently hydrogen, C_1 - C_6 alkyl, or $-(CH_2)_n$ aryl;


R^2 is $-(CRR)_n$ -aryl,
 $-(CRR)_n$ -X-aryl,

U.S. Serial No. 09/284,424
Group Art Unit No. 1623



C5
cont'd

U.S. Serial No. 09/284,424
Group Art Unit No. 1623



each R is independently hydrogen, C₁-C₆ alkyl, halogen or hydroxy;

X is O or S;

R³ is C₁-C₆ alkyl,

aryl,

-(CHR)_n-aryl,

-(CHR)_n-substituted aryl,

O

||

-(CRR)_nCOR^a,

-(CRR)_nO(CH₂)_n-aryl,

cycloalkyl,


substituted cycloalkyl,

O


||

-(CRR)_nCNR^aR^a,

U.S. Serial No. 09/284,424
Group Art Unit No. 1623



U.S. Serial No. 09/284,424
Group Art Unit N . 1623



each R' is independently C_1 - C_6 alkyl,
 C_1 - C_6 alkylaryl,
aryl, or
hydrogen;

each J is independently
-NH-SO₂-(C_1 - C_6 -alkyl),
-CO₂ R^b ,
-CONR^b R^b ,
-SO₂NR^b R^b , or
-SO₂ R^b ;

each R^b is independently hydrogen, C_1 - C_6 alkyl, aryl, substituted aryl, arylalkyl, or
substituted arylalkyl;

R^4 is hydrogen,
 C_1 - C_6 alkyl,


$\overset{\text{O}}{\parallel}$
CH₃OC-,
-phenyl, or

$\overset{\text{O}}{\parallel}$
 C_1 - C_6 alkyl C-;


R^5 is C_1 - C_6 alkyl-CO-,
-(CH₂)_n aryl,

$\overset{\text{O}}{\parallel}$
 C_1 - C_6 -alkylOC-,
 C_1 - C_6 -alkyl-X-(CH₂)_nCO-,
 $\overset{\text{O}}{\parallel}$
 C_1 - C_6 -alkyl-X-(CH₂)_nOC-,

U.S. Serial No. 09/284,424
Group Art Unit No. 1623




R^{5a} is



5
contd

U.S. Serial No. 09/284,424
Group Art Unit No. 1623



C5
concd

~~R^6 is hydrogen, C_1 - C_6 alkyl, $-(\text{CH}_2)_n$ aryl, $-(\text{CH}_2)_n\text{CO}_2\text{R}^a$, or hydroxyl substituted C_1 - C_6 alkyl;~~

~~R^7 is hydrogen, $-\text{S}-(\text{C}_1-\text{C}_6\text{-alkyl})$, or $-\text{SO}_2-(\text{C}_1-\text{C}_6\text{-alkyl})$;~~

~~each n is independently 0 to 3, and the pharmaceutically acceptable, salts, esters, amides, and prodrugs thereof.~~